Bayer Settles Half of Yaz®,Yasmin® Lawsuits Alleging Blood Clots, Deep Vein ThrombosisOverview: Bayer has settled 3,490 lawsuits alleging that the oral contraceptives Yaz® and Yasmin® caused blood clot-related conditions, including deep vein thrombosis (DVT) and pulmonary embolism (PE). The company has spent $750 million to settle these cases, and half of the Yaz and Yasmin suits alleging blood clots remain. Furthermore, the company still has some 5,000 more lawsuits claiming that Yaz or Yasmin caused other injuries, such as gallbladder disease. In total, over 12,000 lawsuits have been filed against Bayer over Yaz and Yasmin.

  • More than 12,000 lawsuits alleging injuries from Yaz and Yasmin have been filed against Bayer
  • Bayer has spent $750 million to settle 3,490 lawsuits alleging deep vein thrombosis and pulmonary embolism, half of these cases remain
  • There are nearly 5,000 lawsuits alleging other injuries such as gallbladder disease and sudden death

Product: Yaz®, Yasmin® (Drospirenone and Ethinyl Estradiol)

Manufacturer: Bayer AG

Side Effects & Complications

  • Blood Clots
  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Gallbladder Damage
  • Heart Attacks
  • Stroke

Bayer Still Facing 8,000 More Yaz®, Yasmin® Lawsuits

According to Bayer’s third quarter stockholder report, the company has shelled out $750 million to settle 3,490 lawsuits over Yaz and Yasmin. These were only half of the cases alleging blood clots from the birth control pills. Some 3,800 lawsuits alleging deep vein thrombosis and pulmonary embolism have yet to be settled, potentially bringing up the cost of litigation to $1.5 billion. Beyond this, Bayer still had to deal with an additional 5,000 suits claiming other injuries from Yaz or Yasmin, including gallbladder disease and sudden death.

Yaz and Yasmin Linked to Risk of Blood Clots

There are more than 12,000 lawsuits in the United States claiming injuries from Yaz and Yasmin, and this number may be on the rise as more evidence showing the risk of blood clots associated with the pills emerges. In April, the U.S. Food and Drug Administration (FDA) updated the label on Yaz, Yasmin and other drugs containing the synthetic hormone drospirenone. The updated label warns users that the risk of blood clots may three times as high in women taking pills such as Yaz or Yasmin. A recent study published in the journal Contraception found that women taking pills with drospirenone are 77 more likely to suffer from  venous thromboembolic events and twice as likely to experience an arterial thromboembolic event.